WST · West Pharmaceutical Services Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted-diluted EPS non-GAAP | $2.37 | second-quarter 2026 | — |
|
|
|||
| Capital expenditures | $85.9M | second-quarter 2026 | — |
|
|
|||
| HVP Components net sales | $424.1M | second-quarter 2026 | — |
| HVP Delivery Devices net sales | $131.2M | second-quarter 2026 | — |
|
|
|||
| Operating cash flow | $213.9M | second-quarter 2026 | — |
|
|
|||
| Proprietary Products Segment net sales | $722.6M | second-quarter 2026 | +16.6% |
|
|
|||
| Shares repurchased | 1.8M | first six months of 2026 | — |
| Standard Products net sales | $167.3M | second-quarter 2026 | — |
|
|
|||
| West Vantage Segment net sales | $149.7M | FY2026 Q2 | +2.0% |
|
|
|||
| Free cash flow non-GAAP | $47.2M | first quarter of 2026 | — |
| Organic net sales growth non-GAAP | 4.3% | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
WST
this stock
West Pharmaceutical Services Inc
|
$24.00B | +24.0% | +2.0% | 43.7 | 3.4% |
|
ISRG
Intuitive Surgical Inc
|
$124.82B | -37.6% | +20.5% | 40.6 | 1.9% |
|
MDLN
Medline Inc.
|
$51.60B | -6.5% | +11.5% | — | 2.2% |
|
BDX
Becton Dickinson & Co
|
$45.64B | +10.0% | +8.2% | 62.9 | 3.8% |
|
ALC
Alcon Inc
|
$33.62B | -12.5% | +10.5% | — | 2.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| WST | +4.0% | -6.8% | +37.0% | -5.0% | +24.0% |
| SPY | +1.1% | +0.3% | +8.2% | +0.0% | +9.6% |
| vs SPY | +2.9% | -7.1% | +28.8% | -5.1% | +14.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.